SCHEMBL19005073

SCHEMBL19005073

CCn1cc(-c2ccc(N)c(NO)c2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.52
PIK3CA P42336 2/20 0.52
PIK3CB P42338 2/20 0.52
PI4KA P42356 2/20 0.52
PIK3CG P48736 2/20 0.52
PI4KB Q9UBF8 2/20 0.52
LRRK2 Q5S007 1/20 0.46
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 2/20 0.42
GSK3B P49841 3/20 0.41
DYRK1A Q13627 3/20 0.41
PIP5K1C O60331 1/20 0.41
ACSS2 Q9NR19 1/20 0.41
WNT1 P04628 1/20 0.41
PAICS P22234 3/20 0.40
ABL1 P00519 4/20 0.40
CSF1R P07333 4/20 0.40
LYN P07948 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18985713 0.83 PIK3CD (0.58) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005196 0.83 PIK3CD (0.55) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19004903 0.82 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005096 0.82 PAICS (0.38) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005034 0.82 HDAC1 (0.55) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL20732691 0.81 PIK3CD (0.37) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005094 0.81 PAICS (0.37) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005273 0.81 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005296 0.81 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL19005256 0.79 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10894784-B2 Heteroarylbenzimidazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-01-19 US disclosed
US-20190047980-A1 HETEROARYLBENZIMIDAZOLE COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-02-14 US disclosed
WO-2017102091-A1 HETEROARYLBENZIMIDAZOLE COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047980-A1 HETEROARYLBENZIMIDAZOLE COMPOUNDS CCNI, CCNT2, CDK2 PIK3CD 455/4885PIK3CA 241/4885PIK3CB 284/4885
US-10894784-B2 Heteroarylbenzimidazole compounds CCNI, CCNT2, CDK2 PIK3CD 455/4885PIK3CA 241/4885PIK3CB 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.